-+ 0.00%
-+ 0.00%
-+ 0.00%

CUE BIOPHARMA RECEIVES FDA FEEDBACK ON PRE-IND BRIEFING DOCUMENT REINFORCING COMPANY’S INTENTION TO ADVANCE IND SUBMISSION FOR CUE-401 TO ADDRESS UNMET NEED IN THE TREATMENT OF AUTOIMMUNE DISEASE

Reuters·06/24/2025 20:48:39

Please log in to view news